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Prednisone is an anti-inflammatory steroid drug widely used in clinical practice. However, no high-
performance liquid chromatographic (HPLC) method has been described in the literature for the 
determination of prednisone in capsules until now. Thus, an HPLC method was developed using a 
C18 (250x4.0, 5 µm) column, with methanol:water (70:30) as mobile phase at a flow rate of 1 mL/min 
and detection at 240 nm. The developed method was validated following current Brazilian legislation. 
Additionally, linearity was assessed by evaluating the assumptions of normality, homoscedasticity, and 
independency of residuals, and the fit to the linear model. The method showed linearity (r2>0.99) over 
the range of 14.0-26.0 µg/mL, selectivity, precision (RSD<2.0%), robustness, and accuracy (average 
recovery of 100.05%). The chromatographic procedure was applied for assay and uniformity content 
determination of three different batches of prednisone capsules, showing to be suitable for their quality 
control.
Uniterms: Prednisone. Capsules. High performance liquid chromatography/validation. Linearity 
assessment.
INTRODUCTION
Anti-inflammatory drugs have been widely used in 
clinical practice due to their ability to suppress inflammation 
signs and symptoms and also to exert a strong antipyretic 
and analgesic effect (Rang et al., 2007; Goodman et al., 
2010). Anti-inflammatory drugs may be classified as 
non-steroidal drugs (NSAIDs) and steroids, the latter also 
referred to as corticosteroids (Gilroy et al., 2003).
Corticosteroids are naturally produced by the adrenal 
cortex and are involved in carbohydrate metabolism 
regulation and electrolyte balance. Also, they present anti-
inflammatory and immunosuppressive properties (Laan, 
Jansen, Van Riel, 1999; Goodman et al.,, 2010).
While presenting a slower onset of action compared 
to NSAIDs, steroids have therapeutic advantages such 
as less interference in hemostasis and lower incidence 
of gastrointestinal disorders. Moreover, they possess 
considerably higher anti-inflammatory activity and a more 
favorable cost-effectiveness ratio (Rodrigues et al., 2008).
Prednisone, a glucocorticoid, is a potent synthetic 
anti-inflammatory drug widely used in clinical practice for 
the treatment of inflammatory and autoimmune diseases. 
Prednisone is a prodrug extensively converted in vivo to 
its active form, prednisolone, through hepatic metabolism 
(Sagcal-Gironella et al., 2011).
Prednisone is recognized as a safe and effective drug 
and is present in the Brazilian List of Essential Medicines 
(Brasil, 2014). Currently, tablets (reference, similar, and 
generic drugs) and capsules (prepared only in pharmacies) 
are available in the Brazilian market. The production of 
capsules containing prednisone by pharmacies is relevant 
for the population since it allows achieving individual 
needs of patients and ensures the availability of drug 
products at affordable costs (Gennaro, 2004; Markman 
et al., 2007). However, compound drugs must prove their 
efficacy and safety; therefore, the use of suitable analytical 
methods for quality control is imperative.
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Analytical methods for determination of prednisone 
content in tablets and active pharmaceutical ingredients 
(APIs), but not for capsules, have been published in the 
literature. Barancelli and Ferreira (2007) have analyzed 
prednisone in capsules by means of a spectrophotometric 
method as described in the monograph of prednisone 
tablets in the Brazilian Pharmacopeia (Farmacopeia 
Brasileira, 2010). It is known that spectrophotometric 
methods may not be selective. Excipients used in the 
formulation may be absorbed in the same wavelength as 
that of the drug, which limits its use. A high-performance 
liquid chromatographic method is described in the 
Brazilian Pharmacopeia for the assay of prednisone 
API. However, the use of tetrahydrofuran in the mobile 
phase limits its use, since this solvent has a cut-off at high 
wavelengths, is toxic, and is unstable due to the formation 
of peroxides when it is exposed to the air.
In this context, this study describes the development 
and validation of a liquid chromatographic method 
to determine prednisone in capsules. Validation was 
performed according to current Brazilian legislation. 
Additionally, the assumptions for a linear regression model 
were evaluated. The developed method was applied for 
the assay and content uniformity determination of three 
batches of prednisone capsules.
MATERIAL AND METHODS
Reagents
Prednisone reference standard (99.5% purity) was 
obtained from the United States Pharmacopeia (Rockville, 
USA) (Figure 1). Methanol HPLC grade was from J. T. 
Baker (Xalostoc, Mexico), and sulfuric acid and ethanol 
analytical grade were from Sigma-Aldrich (Saint Louis, 
USA). Water used for preparing all solutions and samples 
was purified in a Direct-Q 3 System from Millipore 
(Bedford, USA).
Capsules of gelatin containing 20 mg of prednisone 
in three different formulations, prepared by three 
compound pharmacies with undisclosed origin, were 
used. Samples of prednisone API as well as a mixture of 
the excipients (placebo) have also been provided. The 
composition of each batch and the role of each excipient 
are presented in Table I.
Apparatus and chromatographic conditions
Chromatography was carried out using an HPLC 
system (Agilent 1200 Infinity Quaternary LC system) 
coupled with a diode-array detector (Agilent 1200 
Infinity, G DAD). Chromatographic separation was 
accomplished in a Zorbax C18 (250 x 4.0 mm, 5.0 µm) 
column from Agilent Technologies (Santa Clara, USA). 
The experiments were performed at room temperature 
(25 ºC) with a mobile phase consisting of methanol:water 
(70:30, v/v) at a flow-rate of 1.0 mL/min. The injection 
volume was 20 µL and detection was at 240 nm. The 
mobile phase was filtered at 0.45 µm membrane and 
degassed prior to use.
Linearity and range
Linearity was assessed from three analytical 
curves for prednisone reference standard solutions in the 
concentrations of 14.0, 16.0, 18.0, 20.0, 22.0, 24.0, and 
FIGURE 1 - Chemical structure of prednisone.
TABLE I - Composition of batches A, B, and C
Excipients
Batches (%)
Role
A B C
Colloidal silicon dioxide 0.5 1.0 4.2 Glidant
Sodium lauryl sulfate 1.5 - - Tensoactive
Magnesium stearate 0.5 - - Lubricant
Lactose monohydrate M200 82.5 - 79.1 Diluent
Polyvinylpyrrolidone (Kollidon K30) 15.0 - 16.7 Binder
Corn starch - 67.5 - Diluent
Talc - 30.5 - Glidant
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26.0 µg/mL. Work solutions were obtained by diluting 
three independent stock solutions at 100 µg/mL.
The obtained results were plotted in a graph of 
analyte concentration (µg/mL) versus response (peak 
area). Both regression equation and the determination 
coefficient (r2) were obtained by ordinary least squares 
method. The obtained data were further statistically 
analyzed to prove that they met the assumptions for a 
linear regression. Analysis of variance (ANOVA) was used 
to determine how well the model fit the data. The Jacknife 
test was used in order to evaluate the presence of outliers. 
Ryan-Joiner, Durbin-Watson, and Brown-Forsythe tests 
were performed to assess normality, independency, and 
homoscedasticity of residuals, respectively.
Selectivity
Excipient samples used in the three batches (A, B, 
and C) were prepared in order to check any interfering peak 
eluting at the same retention time as the peak of prednisone 
at the lowest concentration (14.0 µg/mL). Selectivity was 
further assessed by analyzing prednisone peak purity. The 
solutions of placebo were prepared by weighing an amount 
of excipient equivalent to the amount of excipient present 
in capsules containing 5 mg of prednisone.
Precision
Repeatability (intra-day precision) was evaluated 
calculating the relative standard deviation (RSD) of six 
independent solutions of prednisone API at 20.0 µg/mL. 
Intermediate precision (inter-day precision) was assessed 
repeating the procedures of repeatability on two different 
days by two analysts, and the RSD of the 12 solutions was 
determined.
Accuracy
Accuracy was estimated by spiking known amounts 
of prednisone reference standard at 100.0 µg mL-1 to a fixed 
amount (50 mg) of placebos. Subsequently, these solutions 
were diluted, and recovery from the levels of 80%, 100%, 
and 120% (16.0, 20.0, and 24.0 µg/mL, respectively) 
was calculated in triplicate. Recovery was determined as 
the percentage ratio between the average concentration 
obtained experimentally and the corresponding theoretical 
concentration at each level.
Robustness
The parameters ratio of methanol in mobile phase, 
mobile phase flow-rate, and oven temperature were 
varied in order to test robustness as shown in Table II. Six 
determinations were carried out at 100% of the working 
concentration (20.0 µg/mL) in each of the seven conditions 
proposed. The mean results were compared by analysis of 
variance (ANOVA) using the F test.
Analysis of capsules containing prednisone
The optimized and validated method was employed 
in assay and content uniformity determination of three 
batches of prednisone capsules. Assay was performed 
in triplicate for each batch. Samples of capsules were 
prepared by weighing an appropriate mass of the powder 
equivalent to the amount of prednisone required to 
obtain the concentration used in the developed method 
(20.0 µg/mL), using the average weight previously 
obtained. The content uniformity test was assessed as 
described in Brazilian Pharmacopeia (Farmacopeia 
Brasileira, 2010).
RESULTS AND DISCUSSION
Chromatographic method
Since there are no methods described in the literature 
for determination of prednisone in capsules, those for 
determination in API and in tablets were primarily tested in 
this study. However, these methods were not reproducible, 
being not suitable for the quantification in capsules.
Barancelli and Ferreira (2007) proposed the 
use of an ultraviolet spectrophotometric method for 
determination of prednisone in capsules, using a 
method described in Brazilian Pharmacopeia for tablets. 
However, according to our results, this method was not 
TABLE II - Parameters and conditions proposed to evaluate robustness
Parameters Nominal 1 2 3 4 5 6
Ratio of methanol (%) 70 67 73 70 70 70 70
Mobile phase flow-rate (mL/min) 1 1 1 1 1 0.8 1.2
Temperature (°C) 25 25 25 20 30 25 25
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selective, as some excipients used in the formulation 
were absorbed significantly at the same wavelength 
as prednisone. The solutions of placebo from batches 
A, B, and C presented absorbances of about 9.9%, 
5.0%, and 5.4% of the absorbance of the reference 
standard solution. Therefore, the results found with the 
spectrophotometric method were overestimated when 
compared to those using the chromatographic method 
developed in this study.
An HPLC method for prednisone analysis in API, 
employing tetrahydrofuran in the mobile phase, was also 
tested. The high amount of tetrahydrofuran in the mobile 
phase resulted in an unstable baseline, which may lead to 
uncertainty of measurement. The probable reason for this 
behavior is the peroxide formation, which occurs when 
tetrahydrofuran is exposed to light, as already described 
in the literature (Clark, 2001).
In this context, a new chromatographic method was 
developed and validated. Tetrahydrofuran was excluded 
and the mobile phase was composed of methanol and 
water in an optimized ratio to achieve a reduced analysis 
time. The best conditions were those described in the 
section Apparatus and chromatographic conditions, 
which were used to validate the method. The retention 
time for prednisone was 3.6 minutes. Plate number and 
tailing factor were 8,793 and 1.154, respectively, showing 
method suitability.
Linearity
The analytical curve, as well as parameters of the 
linear regression is presented in Figure 2 and Table III. The 
coefficient of determination (r2) obtained was higher than 
the preconized minimal value of 0.99. Since a high value 
of determination coefficient does not necessarily mean a 
linear model, the assumptions concerning the residuals 
were tested (Souza, Junqueira, 2005).
No outliers were found according to the Jacknife 
test, at a significance level of 0.05. Normality of residual 
distribution was confirmed by the Ryan-Joiner test, as the 
correlation coefficient obtained (0.9815) was higher than 
the critical value (0.9614) for p>0.10.
Independency of residuals was verified using the 
Durbin-Watson test. There was no correlation between the 
residuals; i.e., there was no effect of any treatment on the 
subsequent treatment. The homoscedasticity was proved 
by the Brown-Forsythe test, with tL (t from Levene) of 
0.85, lower than critical t value (2.093). Thus, there was 
no statistical difference between variances obtained for 
all tested levels; i.e., the variance of errors was constant 
across observations.
The regression significance was evaluated using 
ANOVA. The calculated F value (4836.21) was higher 
than the critical value (4.38075); therefore, regression 
was significant. Deviation from linearity (lack of fit) was 
also assessed by ANOVA. The calculated F value (0.319) 
was lower than the critical value (2.9582), showing the 
suitability of the linear model.
Selectivity
Selectivity was assessed by comparing the 
chromatograms obtained with a sample of prednisone 
reference standard at 14.0 µg/mL with those of placebo 
samples in order to check the presence of interferences. 
No chromatographic peaks were observed in the 
chromatograms of placebo samples (batches A, B, and C) 
at the same retention time as prednisone in the reference 
standard sample (Figures 3A and 3B).
Chromatographic peak purity of prednisone in 
capsule samples was confirmed by means of ChemStation 
software (Agilent, USA). Moreover, the spectrum of 
absorbance in the range between 200 to 400 nm for 
capsule samples, obtained with ChemStation software 
(Figure 3C), exhibited a similar profile, with minimums 
and maximums in the same wavelength of the spectrum 
of prednisone reference standard found in the literature 
(Moffat, Osselton, Widdop, 2004).
TABLE III - Regression parameters of analytical curve
Regression parameters Results
Coefficient of determination (r2) 0.9961
Slope ± standard deviation 44.912 ± 0.646
Intercept ± standard deviation 6.535 ± 13.172
Range (%) 70 – 130
Number of points 7
FIGURE 2 - Analytical curve obtained in linearity evaluation.
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Precision
The content of prednisone in samples at 20.0 µg 
mL-1 used in the evaluation of intra-day precision is 
shown in Table IV. In the evaluation of inter-day precision 
(assessed on two different days by two analysts), the mean 
content was 99.38% and RSD was 0.88%. According to 
current Brazilian legislation, RSD must not exceed the 
limit of 5.0% (ANVISA, 2003). Therefore, the developed 
method showed appropriate repeatability and intermediate 
precision.
Accuracy
Accuracy was calculated comparing the responses 
obtained for samples of prednisone reference standard with 
those obtained for placebo spiked with prednisone at 16.0, 
20.0, and 24.0 µg mL-1 (levels 80%, 100%, and 120%). 
The test was applied separately for batches A, B, and C. 
The recovery found for all concentrations and batches was 
between 98% and 102% (Table V), demonstrating method 
accuracy (Green, 1996; ICH, 2005).
Robustness
The mean content obtained in the evaluation of 
robustness in the seven tested conditions (n = 6) ranged 
from 98.94% to 99.39% with RSD between 0.50% and 
0.62%. The result obtained for each tested condition was 
compared using ANOVA. The calculated F value (0.48) 
FIGURE 3 - (A) Chromatograms of prednisone reference standard at 14.0 µg mL-1 and placebo sample using the optimized 
conditions of the chromatographic method. (B) Expanded chromatograms of (A). (C) Spectrum of ultraviolet absorbance in the 
range 200-400 nm for prednisone.
TABLE IV - Data from repeatability and intermediate precision
Replicate
Content (%)
Day 1 Day 2
1 98.31 99.97
2 100.39 99.28
3 100.86 98.74
4 98.96 98.16
5 99.68 98.50
6 100.27 99.48
Mean 99.75 99.02
RSD (%) 0.96 0.68
TABLE V - Data from accuracy experiments
Batch Level (%) Recovery (%)
A 80 100.61
100 99.94
120 100.79
B 80 99.19
100 99.77
120 99.56
C 80 100.51
100 99.73
120 100.32
Mean 99.38
RSD (%) 0.88
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was lower than the F critical (2.37) at the significance 
level of 5%, showing that there was no significant 
statistical difference between evaluated means. Therefore, 
the method can be considered robust in the assessed 
conditions.
Analysis of capsules
After development and validation, the proposed 
method was used to evaluate content and uniformity 
of dosage units (using the content uniformity test) 
in three batches of prednisone capsules. In assay, six 
replicates of the samples were prepared for each batch. 
The acceptable level of prednisone was 95% to 105% 
of the labeled amount. The results are shown in Table 
VI. Only batch A showed content within the established 
range, meeting the assay test. Batches B and C presented 
results out of specification and therefore would not be 
approved. 
The content of prednisone for batches A, B, 
and C were 105.10%, 96.08%, and 97.17% when the 
spectrophotometric method was employed (Barancelli, 
Ferreira, 2007). These results were higher than those 
obtained with the chromatographic method. Therefore, the 
spectrophotometric procedure overestimated the results 
due to the interferences of excipients.
The content uniformity test was assessed assaying 
individually the amount of prednisone in 10 capsules. This 
procedure was performed for the three available batches 
(Table VII). The mean contents and the standard deviations 
were used to calculate the acceptance value, which must 
not be higher than 15.0.
The three batches complied with the recommended 
requirements for the test of content uniformity, since the 
acceptance values (2.52, 8.84, and 12.46 for batches A, 
B, and C, respectively) were lower than the maximum 
allowed value (Farmacopeia Brasileira, 2010).
CONCLUSIONS
The developed and validated method proved to be 
linear, precise, accurate, selective, robust, and therefore 
appropriate for assessing the quality of capsules containing 
prednisone. Moreover, this method has advantages in 
terms of speed of analysis when compared with the 
methods described in the literature for the analysis of 
prednisone in API and tablets. Also, it excluded the 
inconvenience of working with tetrahydrofuran, an 
unstable and considerably toxic solvent. Therefore, this 
method can be used in quality control of capsules and 
formulation studies.
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